Clozapine is an atypical antipsychotic, used as a last-line therapy for patients with treatment-resistant schizophrenia. Despite being an effective medication, its clinical use is limited due to the substantial risk of adverse effects, including cardiotoxicities such as myocarditis and cardiomyopathy. These life-threatening toxicities are either acute in nature (myocarditis) or develop due to chronic, subclinical inflammation and tissue damage (cardiomyopathy). It is likely that the two are related and arise from similar mechanisms that drive cardiac damage and inflammatory cascades. Critical analysis of the historical hypothesis that clozapine cardiotoxicity is an idiosyncratic IgE-mediated (allergic) hypersensitivity reaction suggests that this mechanism is unlikely, although it currently remains an idiosyncratic adverse drug reaction, with involvement of either innate or cell-mediated immune responses. Instead, the identification of clinically observed risk factors, alongside ever-developing in vitro and in vivo assessment of clozapine-associated reactivity and cellular damage, has led to the development of several plausible mechanisms behind the development of clozapine cardiotoxicity. This review compares the contributions of hyper-catecholamines, altered clozapine metabolism, mitochondrial damage, reactive oxygen species, perturbation of endogenous anti-inflammatory processes and receptor-mediated cell death to develop a modern understanding of the melange of processes that are likely to be implicated in cardiotoxicity. It is likely that these tissue-damaging processes are exacerbated by rapid dose titration and concomitant sodium valproate administration. Although no single initiating or effector mechanism has been confirmed for clozapine cardiotoxicity, the available evidence supports an integrated model in which direct cellular injury, altered metabolism, inflammatory amplification and immune cell responses may contribute to the observed damage. Clinical and experimental information should be considered holistically in future research that aims to improve the safe and effective use of clozapine.
Obesity represents a chronic, relapsing, and multifactorial neuroendocrine disease with profound metabolic, cardiovascular, and oncologic consequences. The therapeutic landscape has undergone a paradigm shift with the emergence of incretin-based pharmacotherapies, particularly long-acting peptide agonists targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways. These agents exhibit complex, nonlinear pharmacokinetic (PK) and pharmacodynamic (PD) profiles, necessitating rigorous quantitative clinical pharmacology frameworks to optimize therapeutic outcomes. This review provides an overview of the clinical pharmacology of modern anti-obesity drugs, with an emphasis on PK/PD relationships, exposure-response analyses, covariate effects, and population pharmacometric modeling as the mechanistic basis for precision dosing strategies. Long-acting incretin-based therapies, including semaglutide, tirzepatide, and emerging triple agonists, achieve extended half-lives (t½: 5–7 days) through molecular engineering strategies such as albumin binding and fatty acid conjugation. Population PK analyses reveal that body weight, renal function, and sex are significant covariates explaining 20–40
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, despite advances in targeted therapy and immunotherapy. Dysregulation of the Cyclin D–CDK4/6–Rb axis is common across NSCLC subtypes, supporting CDK4 as a potential therapeutic target. Coumarin derivatives, which are structurally versatile and synthetically tractable scaffolds, have gained attention in kinase-directed drug discovery. This review critically summarizes current progress in the structure-based design of coumarin-derived compounds targeting CDK4 and discusses their potential therapeutic relevance in NSCLC. Particular emphasis is placed on computational drug discovery strategies, medicinal chemistry optimization, and the experimental approaches required for biological validation. Recent studies have integrated molecular docking, molecular dynamics simulations, and free-energy analyses to refine the hinge region interactions and optimize ATP-pocket complementarity. Rational substitutions at key positions of the coumarin scaffold have been proposed to improve predicted binding stability, selectivity, and pharmacokinetic properties through structure-based optimization strategies. Machine learning–assisted Structure-activity Relationship (SAR) modeling and early absorption, distribution, metabolism, and excretion (ADME) prediction increasingly guide compound prioritization. Emerging evidence suggests that enhanced CDK4 selectivity and rational combination strategies may improve the therapeutic index in NSCLC. Coumarin-based scaffolds are promising platforms for CDK4-targeted drug development. While computational and preclinical findings are encouraging, comprehensive selectivity profiling and translational validation remain essential for advancing these candidates in NSCLC therapy.
Systemic lupus erythematosus (SLE) remains a major therapeutic challenge due to its complex pathophysiology and the limitations of current treatment strategies. This review evaluates the potential of nanoparticle-based drug delivery systems as a novel therapeutic approach for improving SLE management. Recent advances in nanotechnology have enabled the development of drug delivery systems such as liposomes and polymeric nanoparticles designed to enhance drug solubility, stability, and targeted delivery while minimizing systemic adverse effects. Preclinical studies demonstrate that these nanocarriers can selectively deliver immunosuppressive agents to affected tissues, resulting in improved therapeutic efficacy and reduced off-target toxicity. However, challenges remain regarding long-term safety, regulatory approval pathways, and scalability for large-scale production. Nanoparticle-based therapeutic strategies offer promising opportunities to overcome key limitations of conventional SLE treatments. Although further investigation is needed to address safety and translational barriers, continued development of nanomedicine platforms holds significant potential to improve disease control and enhance the quality of life for patients with SLE.
Cancer is a massive health problem worldwide that has many molecular complexities and drug-resistant issues. Phytochemicals have gained attention for their anticancer effects, which can act on multiple targets. The aim of review is to investigate the phytochemical composition and anticancer mechanism of Drynaria quercifolia. Findings in recent years have established that Drynaria quercifolia contains various kinds of phytochemicals (such as flavonoids/phenolic acids/terpenoids), which inhibit the proliferation of cancer cells (SAOS2/A549). These compounds also induce apoptosis and oxidative stress and interfere with key signalling pathways (NF-κB/PI3K/AKT). In addition, some recent studies have shown the results of autophagy and ferroptosis. Drynaria quercifolia has potential bioactive compounds that can be utilized for anticancer purposes. However, further in vivo and clinical studies will be required to prove its therapeutic usefulness and to demonstrate its translatability.
